SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025
SignaBlok Achieves Key in Vivo Proof of Concept for Treatment of Cancer and Sepsis
Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis - September 18, 2013
SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer. - October 03, 2012
SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of Atherosclerosis
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis. - July 12, 2012
SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning). - January 12, 2012